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In this thesis the genetic and non-genetic determinants and clinical consequences of 
impaired lung function were studied. Especially, genetic epidemiological studies had 
a great share in this work. Here, comprehensive study designs were used including 
GWAS, EWAS, and Genome-wide linkage to investigate which genetic and epigenetic 
changes are significant contributors to disease onset and progression. For this, we 
integrated population genetics with experimental clinical research. In this chapter, 
the main findings, research challenges, clinical relevance and future directions are 
discussed.
Main findinGs and challenGes
epidemiology of cOPd
Epidemiological research is crucial to gain insight into the occurrence of diseases, to 
support informed decision making and develop public health interventions and strategies 
to address risk factors (1). Alongside with other research disciplines, epidemiological 
research is essential and aims to answer questions like: how big is the problem? What 
is the risk of acquiring the disease in a certain amount of time? And which risk factors 
are important?
In chapter 2, we studied the epidemiology of COPD. COPD is the third leading 
cause of death worldwide and thereby a major public health problem (2). In de last 
decade, the number of COPD cases worldwide increased by 28% and this number 
is expected to grow in the future (3). We investigated the epidemiology of COPD in 
15,000 participants of the Rotterdam Study who were followed for up to 25 years. In the 
absence of a clinical diagnosis of asthma in the electronic medical records, COPD was 
diagnosed based on a pre-bronchodilator obstructive spirometry (FEV1/FVC < 0.70). In 
absence of an interpretable spirometry within the Rotterdam Study, cases were defined 
as having COPD diagnosed by a physician on the basis of clinical presentation and 
obstructive lung function measured by the general practitioner or respiratory physician. 
We reported on the prevalence and the incidence of the disease, and investigated 
differences by sex and smoking status. 
One of the challenges in epidemiological cohorts studies is, that researchers 
often deal with historical changes that they have to consider in the sake of a good 
interpretation of the study results. In the Rotterdam study for example, spirometry was 
introduced after 2001, meaning that for a subset of COPD cases the diagnosis was 
based on medical chart records only. Should we have presented the prevalence and 
incidence data of COPD in the total population only, then we would have missed an 
interesting piece of information that enriches our knowledge about the incidence of 
COPD in different settings. Subgroup analyses were required to highlight different study 
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results (Table 1). A higher incidence of COPD was found when diagnosis was based on 
spirometry (only) as compared to a clinically based diagnosis, which can be attributed 
to the inclusion of asymptomatic COPD subjects who  frequently still have mild airflow 
limitation.  Since mild COPD cases rarely seek medical attention, the incidence of 
COPD is frequently underestimated in clinical settings. 
Table 1: Prevalence and incidence data according to different classification methods in the total 
cohort and in the sub-groups (spirometry versus medical charts group)
spirometry data Medical records data combined data
N=7,153 N=7,466 N=14,619
cOPd GOld 
Prevalence 5.3% 4.2% 4.7%
Incidence 11.7/1,000PY 5.8/1,000PY 8.9/1,000PY
cOPd lln
Prevalence 3.4% 4.2% 3.8%
Incidence 5.2/1,000PY 5.8/1,000PY 5.5/1,000PY
COPD: Chronic obstructive pulmonary disease; GOLD: Global initiative for Obstructive Lung 
Disease; LLN: lower limit of normal; PY: person years
Another historical change is the introduction of “better” (i.e. more accurate) cut-off 
values of FEV1/FVC to define airflow limitation. In the same chapter, we presented the 
incidence figures of COPD according to either the fixed 0.70 ratio of FEV1/FVC (as 
recommended by the Global initiative for Obstructive Lung Disease [GOLD]) or the 
lower limit of normal (LLN; as recommended by the Global Lung function Initiative 
[GLI]) (Table 1) (4-7). The question remains whether we really have to replace the 
fixed ratio with the LLN. Several studies claim that using the fixed 0.70 FEV1/FVC 
ratio overestimates the diagnosis of COPD in older individuals due to the inclusion of 
asymptomatic subjects with mild COPD (GOLD I) (6, 8, 9), while others state that mild 
COPD might be a good marker for preclinical disease (6). Importantly, the new criteria 
does not consider subjects with mild COPD (GOLD I) as “true” COPD cases, even 
though we have shown in the Rotterdam Study that even subjects with mild airflow 
limitation (i.e. mild COPD) have an increased risk of cardiovascular mortality (10), all-
cause mortality (11) (figure 1), and future severe exacerbations compared with control 
subjects with normal spirometry (12). 
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figure 1 all-cause mortality in cOPd in The Rotterdam study, stratified by cOPd severity
The global initiative for chronic obstructive lung diseases (GOLD) defined COPD as a 
preventable and treatable chronic respiratory disease (13, 14). Although research efforts 
broadened our understanding of the disease, we are still unable to unravel the exact 
pathophysiological mechanisms of this disease, nor we are able to define accurate 
biomarkers of COPD (15-21). Thereby, we are left with a progressive disease that forms 
a huge burden on the quality of life of millions of people worldwide (14). The only 
bright spot for patients with COPD are medications for symptoms relief that help them 
improve their quality of life (22). However, this change in COPD treatment forms a 
methodological challenge in epidemiological research of the ‘natural course’ of COPD, 
because the more treatment options are available, the more difficult it is to capture the 
differences in severity that arise, due to effect of treatment.
Finally, COPD is an age-related disease. Patients with COPD often present with 
multi-morbidity including cardiovascular and cerebrovascular disease (22). For this 
very reason, researchers encounter difficulties studying associations between COPD 
and other age related diseases, such as dementia, because the more advanced the 
disease stage is, the more researchers will deal with informative missingness in their 
data, leading to a possible bias in the generated results (23).
Genome-wide association studies (GWas)
GWAS associations can typically tag multiple genetic variants in the same region that 
are highly correlated (or in other words, in linkage disequilibrium (LD)). Correlated 
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variants have an equal likelihood to be causally associated with the disease of interest, 
when assuming no independent effects. The idea behind LD relates to the non-random 
association between one or more loci on the genome (24). The LD between SNPs 
in the same chromosomal region is calculated based on information of the observed 
haplotype frequency of the two SNPs of interest and the frequency of each individual 
SNP (24-26). Although there are many ways proposed to calculate LD (27, 28), it is 
nowadays typically expressed as a measure of squared correlation (r2), or as the relative 
measure of disequilibrium compared to its maximum, as proposed by Lewontin , the 
D prime (D’) (26). However, many web based applications, that provide summaries 
and visualizations of GWAS results often base their LD calculations on r2 only. It is 
important to realize that r2 can only reach its maximum if the allele frequency of the 
two SNPs are similar and the two haplotype frequencies are bigger than zero (25, 29). 
While D’ can be large if any allele of the first locus is seen with one allele of the other, 
and thereby does not depend on allele frequencies as it is the case with r2. As we are 
now in the era of conducting GWA studies with better imputation of rare variants, it 
is desirable to realize that the use of r2 might lead to misleading results about the true 
extent of the LD, simply because of its properties. D’ might be more useful in case we 
are interested in LD measures using a less frequent variant. Nevertheless caution is 
warranted in the interpretation of D’ as well, since D’ can be inflated when the sample 
size is small or if  one of the two alleles is extremely rare (29, 30).
The statistical power to detect associations in GWAS depends on several factors 
such as sample size, effect size of the genetic variant(s), the heterogeneity of the 
phenotype of interest, measurement errors, the distribution of the causal variants in 
the studied population, their frequency and the correlation (LD) with the observed 
genotyped variants (31, 32). 
In chapter 3, we presented two GWA studies of lung function. In the first GWA 
study we investigated a multi-ethnic cohort with more than 90,000 individuals from 22 
studies, of whom 60,000 of European descent. Here, we calculated the heritability and 
genetic determinants of FEV1, FVC and FEV1/FVC, and identified over 50 novel loci, of 
which sixteen genes encode proteins with predicted or established drug targets (33). 
In the second GWA study, we calculated the heritability of and studied the genome-
wide associations with diffusing capacity of carbon monoxide in approximately 8,000 
individuals. Here, we found that the ADGRG6, locus was significantly associated with 
DLCO/VA and that the expression of this gene was decreased in patients with COPD 
and in subjects with decreased diffusing capacity (DLCO/VA) (34). 
sample size
The two GWA studies show roughly similar heritability estimates but differ considerably 
in the number of identified loci (50 novel loci versus 1). This example is a very nice 
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illustration of how sample size (60,000 versus ~8,000 individuals) can increase the 
power to detect (novel) genome-wide significant associations. 
Sample size is one of the most important factors that influence the power to find 
an association in GWA studies. However, since we are dealing with age related traits 
of lung function, the question remains whether it is justified to add individuals from all 
age groups in order to increase sample size and thereby gain power, or to restrict the 
study population to specific age groups (e.g. older individuals) in order to decrease trait 
variability and thereby to increase the power. 
heterogeneity
Phenotypic heterogeneity reduces the power to detect statistically significant 
associations and decreases the magnitude of the risk estimates that are ascribed to 
genetic variations (35). In the GWAS of diffusing capacity of carbon monoxide, we 
had a relatively small sample size to begin with, however we tried to gain more power 
by reducing the heterogeneity of the trait by using not only interpretable but also 
reproducible measurements in the analyses, so that only high quality lung function 
measurements were included (32, 35). 
Intuitively, the greatest power might be obtained when these two important factors 
(sample size and heterogeneity) are in balance. Manchia and colleagues suggested that 
accurate phenotype delineation is maybe even more critical for new genetic discoveries 
than increasing the sample size (35).
Genetic correlation
So far, GWAS had an important role in genetic discoveries beyond detecting trait-SNP 
associations (31). GWAS summary statistics can be used in Mendelian randomisation 
studies to test causal relationships, or to quantify the genomic architecture by assessing 
the LD structure. These can also be used to detect and quantify pleiotropy by means 
of polygenic risk scores or genetic correlation estimations. In chapters 3.1 and 3.2, 
we used summary statistics of the GWASs to test genetic correlations between lung 
function and other traits. An important challenge in genetic correlation studies is, that 
they are sample size dependent (36, 37). In other words, lack of statistically significant 
correlation does not mean lack of pleiotropy, but could be due to lack of power to detect 
pleiotropy. Another challenge in genetic correlations studies is, that genetic correlation 
estimates might be counter intuitive, for example in the case of a negative genetic 
correlation between two lung function measures; FEV1 and DLCO/VA (as measured 
using data from the Rotterdam Study: -0.35 (SE 0.13), p-value=0.009). Several reasons 
are possible to explain negative genetic correlations (figure 2), these include: A) direct 
effect of the causal SNP on the trait, where the SNP has a positive effect on one trait 
and a negative effect on the other, B) a causal SNP that has a positive effect on the first 
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trait, which might be in LD with another causal SNP that has a negative effect on the 
second trait, C) a causal SNP that influences the traits via a mediator that has a positive 
effect on the first trait and a negative one on the second, and finally as an alternative for 
explanation C, D) a causal SNP that affects the first trait which in turn affects the second 
trait in an opposite manner. It is not straightforward to elucidate the exact reason of a 
negative genetic correlation based on the GWAS results only. Therefore, many methods 
are now used to detect genome-wide, regional or single-variant pleiotropy (37-39). 
These methods provide a quantitative assessment of pleiotropy, and have an important 
role in understanding shared genetic effects. 
figure 2 interpretation of a negative genetic correlation between traits with positive phenotypic 
correlation
epigenome-wide association studies (eWas) 
In chapters 3.3 and 3.4, we studied epigenetic associations of blood DNA methylation 
with occupational exposures and diffusing capacity, respectively. Analyses of the 
first study (chapter 3.3) were restricted to 903 never-smokers from lifelines. The 
association between occupational exposure to gases/fumes, mineral or biological 
dust and blood DNA methylation was assessed. Several associations were identified 
and the results were validated in the Rotterdam Study. Finally, methylation-expression 
associations were assessed. In the second study (chapter 3.4), the association between 
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DLCO and DLCO/VA and blood DNA methylation was assessed, after adjustment for 
several covariates including smoking. Data from the Rotterdam Study was used for 
discovery and data from the Framingham Heart Study served as replication panel. Two 
methylation sites were identified and replicated and the role of smoking related genes 
on lung function was discussed. In both studies we hypothesised that DNA methylation 
might act as an intermediate between occupational exposures (chapter 3.3) or smoking 
(chapter 3.4) and lung function impairment. 
A considerable challenge in EWAS is, that EWAS associations can be causal as 
well as consequential, implicating major challenges in study design and interpretations 
of the findings (40, 41). GWAS and EWAS findings are hypothesis generating and 
need replication in independent population-based or clinic-based cohorts. Replicated 
findings are interesting candidates for further experimental research.
In the eWas of diffusing capacity of carbon monoxide (DLCO), we hypothesised 
that the causal effect of smoking would affect methylation levels of the CpG site in 
the AHRR gene. The hypomethylation of the AHRR gene is associated with the low 
expression of another gene, EXOC3. We were able to associate the down regulation of 
mRNA expression of this gene with decreased diffusing capacity in human lung tissue 
(figure 3). It is worthwhile to mention that although we were able to demonstrate clinical 
relevance by linking the methylation status to gene expression and consequently lung 
function decline, the proposed hypothesis is the result of conclusions based on multiple 
steps where each individual step in the triangle is prone to errors that might lead to 
biased results and conclusions. For example, residual confounding by smoking might 
lead to bias in any direction. Also, the biological samples to perform the experimental 
work on, are often derived from a smaller sample of selected clinical patients (e.g. 
undergoing thoracic surgery for lung tumours). Therefore caution must be warranted 
when dealing with such datasets and a well-designed analysis plan is encouraged to 
avoid bias as much as possible. 
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figure 3 Possible pathway through which hypomethylation of cg05575921 (AHRR gene) affects 
diffusing capacity. 
Genome-wide linkage scan 
Although larger studies and more accurate data are needed to increase the power for 
discovery in GWAS, it is unclear whether the findings will help to explain the biggest 
proportion of the missing heritability. Therefore rare variant analyses, including genome-
wide linkage scans might be interesting, as they can be informative for discoveries 
beyond the ones revealed by GWAS so far (Table 2).
Table 2 Possible sources of genetic heritability that might explain the missing heritability 
problem (42, 43)
sources of heritability causes of missing heritability 
common genetic variants - Lack of power in GWAS
Rare genetic variants - Lack of power in WES and WGS 
- Rare variants might explain only a small part of the heritability
- Underrepresentation of rare variants in SNP arrays
epigenetic variants -  Difficulty to control for epigenetic changes that contribute to 
variable gene expression
interaction and epistasis - GWAS  assume additive effects without interaction
- Twin studies do take interaction and epistasis into account
copy number variations, 
insertions, deletions, 
inversions
- These variants are largely under investigated 
- Large sample sizes are needed
-  Often considered as unapproachable by the current genotyping 
and sequencing technologies.
GWAS: Genome-wide association study; WES: Whole exome sequencing; WGS: Whole genome 
sequencing
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COPD is a complex disease with genetics contributing to a substantial part of its 
variability. In chapter 3.5, a genome-wide linkage scan was performed to discover 
rare genetic variants underlying COPD in 142 cases clustered in 27 families from an 
isolated population in The Netherlands; The Erasmus Rucphen Family study (eRf) (44). 
Several linkage peaks were detected (figure 4). Potential causal variants were selected 
for further association testing with COPD in ERF and the Rotterdam Study. The strengths 
of this study are that it provides the opportunity to investigators to point-out genetically 
interesting regions that are associated with COPD. However, a major limitation is often 
the lack of sequencing information in the affected family members, implicating that 
no further analysis could be performed (yet) with two of the three discovered linkage 
peaks.
figure 4 heterogeneity logarithm of the odds (hlOd) score plot for the chromosomes 5, 11 
and 15. X-axis shows chromosome positions and Y-axis shows hlOd score. Red line represents 
hlOd scores for recessive model and green line for dominant model. dashed red line represents 
the level of significance (hlOd=3).
consequences of impaired lung function
In the fourth chapter of this thesis, we tried to understand the link between impaired 
lung function or COPD and other comorbidities, including pulmonary hypertension 
and peripheral arterial disease (PAD).
Pulmonary hypertension
Pulmonary Hypertension is a serious complication in patients with COPD. It evolves due 
to hypoxic vasoconstriction of the small pulmonary arteries, inflammation, mechanical 
stress of hyperinflated lungs and loss of pulmonary capillary bed due to emphysema. 
Pulmonary hypertension may lead to structural changes in the pulmonary arteries and 
can eventually lead to right ventricular hypertrophy and heart failure (45-47).
Pulmonary artery to aorta (Pa:a) ratio, defined as the ratio between the diameters of 
the pulmonary artery and the aorta on transversal images of CT-scans of the thorax, has 
been shown to be a good surrogate marker of pulmonary hypertension in patients with 
COPD and a predictor for an increased risk of severe COPD exacerbations requiring 
hospitalisation (48). In 2,197 participants from the Rotterdam study, we assessed the 
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association between 1-SD increased of PA:A and mortality in the general population 
and in individuals with COPD (chapter 4.1). We demonstrated that higher PA:A ratio 
-as a proxy for pulmonary hypertension- has predictive value on mortality in individuals 
with cOPd, especially in individuals with low diffusing capacity. Importantly, even 
though an increased PA:A ratio is not completely indicative of pulmonary hypertension 
(49, 50), the PA:A ratio might be a good proxy for the impact of pulmonary hypertension 
related mechanisms. Other mechanisms for an increased PA:A ratio include left heart 
disease, pulmonary inflammation, airway remodelling and vasoconstriction, loss of 
capillary beds in the pulmonary circulation and hyperinflation. In conclusion, this 
imaging-based marker - the pulmonary artery to aorta (Pa:a) ratio - has possibly 
important clinical utility, as it might help in identifying those COPD patients who are at 
greater risk of severe exacerbations, hospitalisations and mortality, and thereby provide 
guidance for a more targeted therapeutic decision making (51). 
Peripheral artery disease
Patients with COPD present with multi-morbidity of which most prominently vascular 
disease e.g. atherosclerosis. Peripheral arterial disease (PAD) is one of the manifestations 
of atherosclerosis and appears to be often asymptomatic in individuals with COPD. 
In chapter 4.2, we aimed to investigate the association between COPD and future 
PAD (Ankle Brachial Index ≤ 0.9) longitudinally, and to elucidate the effect of PAD on 
mortality in individuals with COPD. Therefore , we included 3,123 participants from 
the Rotterdam study. We found that, individuals with COPD have a higher (almost 
doubled) risk of developing PAD. People suffering from both COPD and PAD had higher 
mortality rates compared to people without both diseases. Although the increased 
mortality could not be directly attributed to PAD as cause, the occurrence of PAD 
frequently heralds vascular disease in other vascular beds resulting in cardiovascular 
disease (e.g. ischemic heart disease) and cerebrovascular disease (e.g. stroke). 
future directions 
In this section, I discuss my ideas about future research in the field of pulmonary and 
genetic epidemiology. 
Where do we stand now? 
Today, we are dealing with two opposite movements in science. On the one hand, the 
increasing interest of scientific journals to support the open data policies. On the other 
hand, the General Data Protection Regulation (GDPR), that came into force on the 
25th of May 2018, that forces attention and action for personal data protection (52-57). 
At first sight, open data policy and more data protection seem to oppose each other. 
There are several examples in the scientific field, where data sharing has been practiced 
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successfully under the umbrella of ethical and legal norms to the individual privacy. 
For example, the Global Alliance for Genomics and Health (GA4GH), established in 
2013, aims to catalyse genomic science by developing the right legal frameworks to 
assure responsible global sharing of clinical and genetic data (58-62). Such frameworks 
are needed, since they offer legal dimensions to research and data sharing between 
the involved institutes and governments, to protect responsible data sharing. Whether 
GDPR will prohibit data sharing within and between countries is yet to be discovered; 
several issues in GDPR are subject for own interpretation and need to be clarified first 
(54). The good news is that these uncertainties will definitely lead to global discussion 
about future data sharing in research. 
cOPd research 
Despite the enormous effort that is done so far to understand the causes of COPD, 
comprehensive knowledge of the disease pathophysiology of COPD is still lacking 
and epidemiological research in older COPD individuals with more advanced disease 
is challenging. Early identification of individuals who will develop COPD, will not 
only help with preventing disease onset or progression, it would also solve important 
challenges which epidemiological COPD research faces, due to the effect of aging 
and disease severity. Therefore, future research must focus on understanding disease 
pathophysiology and finding a suitable biomarker for COPD. For this, results of large 
(epi)genome-wide association studies must also be considered, as these provide 
simultaneous information on important disease pathways that are involved in the onset 
and/or progression of this heterogeneous and complex disease. 
Genetic discoveries
In the last decade, many consortia of genetic association studies have been set up 
(63-65), in order to facilitate the possibility of meta-analysing genetic data across 
many population-based and clinic based cohorts. We witnessed an increase in genetic 
discoveries by increasing sample sizes of those studies (up to 3 million in the GIANT 
consortium with Height and BMI phenotypes). It is likely to assume that this trend of 
cohorts with increasing sample sizes will continue and that it will probably cumulatively 
explain a substantial amount of the missing heritability in lung function traits and 
respiratory diseases. Importantly, these large meta-analysis cannot be well performed 
without a well-designed analysis plan supported by guidelines for observational studies 
(66, 67), especially harmonization of the data across the cohorts is needed in order to 
obtain meaningful and unbiased results. 
Another approach to increase the chance of discovery, is to use either better 
imputation reference panels, such as the haplotype reference consortium (HRC) panel, 
or to use the more expensive deeper density coverage of variation in the genome using 
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whole exome sequencing (WES) or whole genome sequencing (WGS) techniques. In 
this thesis, we present two GWAS in which we used 1,000 genomes as imputation 
reference panel. Even though we are now in the era of using WGS data with better 
density of coverage of variation in the genome and larger MAF spectrum, the associated 
costs are still a hurdle. Therefore, it might be a reasonable next step to use the HRC 
imputation panel in future GWAS of lung function, given its availability, low costs and 
reasonable accurate imputations of variants with frequency of 0.1% and higher (68). 
While there is a long way ahead of us to find out what we do not yet know in lung 
function genetics (the so called missing heritability; and whether the discovered genetic 
variants are causal), there is also a huge need for translational research to elucidate 
how the – presumably causal - genetic variants contribute to the disease pathogenesis. 
Previous GWAS findings are excellent candidates for experimental studies to provide 
insight in the pathophysiology of disease, including knockout or knockdown animal 
models, experimental studies in human (lung) tissue or studies using relatively novel 
gene editing techniques, such as the CRISPR-cas9 technique (69). These studies are 
essential to understand the pathophysiology of the genetic findings and shows the path 
that we need to follow to link genetic discovery with clinical relevance, and most 
importantly the identification and validation of novel therapeutic targets (figure 5) (70). 
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Figure 5 The journey from genetic discoveries based on genetic association studies to finding 
therapeutic targets and biomarkers for a particular trait or disease.
figure 5 The journey from genetic discoveries based on genetic as ociation studies to finding 
therapeutic targets and biomarkers for a particular trait or disease.
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clinical observational studies 
Regarding the clinical epidemiological studies, our findings could have important 
implications for disease management in patients with COPD. Indeed, routine 
measurement of Pulmonary artery to aorta (PA:A) ratio on the chest CT scan (chapter 
3.1) and/or Ankle Brachial Index screening (chapter 3.2) might contribute to timely 
diagnosis of vascular disease and its consequences. 
Implementing PA:A ratio as a prognostic marker for mortality in patients with 
moderate-to-severe COPD might help with risk stratification and better disease 
management. There is a significant increase in using chest CT imaging in clinical 
practice, either in the context of screening for lung cancer in (heavy) smokers or for 
establishing a diagnosis of pulmonary embolism or ischemic heart disease. On these 
(screening or clinical) CT scans, also the PA:A ratio should be measured systematically 
since it provides prognostic information, especially in patients with COPD. Still, 
several questions remain unanswered. It is interesting to know whether PA:A ratio also 
applies for patients with mild COPD. Finally, repeated measurement of PA:A ratio in 
the population could be useful to understand trajectories of PA:A change and their 
accompanied effect on mortality in COPD. 
There is increasing evidence that COPD and peripheral artery disease (PAD) are 
associated, and our study suggests that COPD might contribute to the development of 
PAD. However, in a next step it would be interesting to investigate the bi-directionality 
of the association between COPD and PAD, and specifically to investigate the vascular 
hypothesis in the development of COPD and emphysema (71). It is indeed tempting to 
speculate that not only pulmonary and systemic inflammation, but also alterations in 
the lung circulation including pulmonary vessel remodelling and endothelial cell death 
are involved in the pathophysiology of COPD (72). 
cOnclusiOn
In conclusion, in this thesis we presented our work on the epidemiology of impaired 
lung function and its consequences on morbidity and mortality. An integrated approach 
to the study of genetic and non-genetic determinants of impaired lung function is 
necessary in order to elucidate the pathophysiology of COPD and other respiratory 
diseases. 
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